Source: Annual Congress 2011 - Role of the biomarkers in airway diseases
Disease area: Airway diseases

Abstract

Introduction:
COPD exacerbations are events in the natural course of the disease characterised by change in patients‘ baseline symptoms which are beyond normal day to day variability and may warrant medical treatment. The early diagnosis and treatment of acute exacerbations is of major importance since they have a given impact on the morbidity, mortality and health care costs associated with COPD.
Objectives:
It is well known that the airway inflammation is enhanced at exacerbations. The purpose of this study is to investigate if the volatile organic compounds (VOCs) detected in the exhaled breath of patients with an acute exacerbation of COPD are different from those detected in patients with a stable disease.
Methods:
Breath samples were collected via a side-steam Teflon tube and measured directly by an ion mobility spectrometer coupled to a multi capillary column (MCC/IMS). VOCs were detected and statistically evaluated in order to discriminate COPD patients with an exacerbation from patients with stable disease.
Results:
Thirteen COPD patients with an acute exacerbation, 46 COPD patients with a stable disease as well as 51 healthy subjects were included in the study. Several peaks were found to differentiate in the group of patients with an acute exacerbation compared to the COPD patients with stable disease and with healthy subjects.
Conclusions:
Our data suggest that specific VOCs can be detected in the exhaled breath of COPD patients with an acute exacerbation indicating possibly the enhanced airway inflammation. The identification of VOCs that characterise the acute exacerbations could be used as diagnostic tool for an exacerbation apart from the clinical criteria.

Rating:

Share or cite this content

Citations should be made in the following way:
V. Besa, K. Darwiche, H. Teschler, U. Sommerwerck, I. Kurth, T. Rabis, J. I. Baumbach, L. Freitag (Essen, Saarbruecken, Germany). Volatile organic compounds (VOCs) in COPD patients with exacerbation. Eur Respir J 2011; 38: Suppl. 55, 4788

Member's Comments

No comment yet.

Related content which might interest you: Volatile organic compounds (VOC) in exhaled breath of patients with COPD Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in chronic and acute airway diseases Year: 2010 Integrating monitoring of volatile organic compounds (VOCs) in asthma and COPD into the routine lung function Source: International Congress 2015 – The next generation of lung function tests Year: 2015 Volatile organic compounds (VOCs) in exhaled air of patients with lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 208s Year: 2003 Breath volatile organic compound (VOC) patterns in adult asthma patients of the ALLIANCE cohort Source: International Congress 2019 – Evaluation of basic science in airway diseases Year: 2019 Volatile organic compounds in exhaled breath are associated with exacerbations in children with asthma Source: Annual Congress 2009 - FeNO and other biomarkers in childhood asthma Year: 2009 Microbial volatile organic compounds (MVOC) and plasticizers in schools in relation to asthma and respiratory symptoms among pupils Source: Eur Respir J 2006; 28: Suppl. 50, 698s Year: 2006 Volatile organic compound (VOC) analysis to differentiate between bacterial and viral respiratory infections in COPD Source: International Congress 2018 – The airway microbiome across the spectrum of airway disease Year: 2018 Diet and alcohol affect exhaled volatile organic compounds (VOCs) Source: Annual Congress 2010 - Exhaled biomarkers: smells like disease Year: 2010 Breath volatile organic compound (VOC) COPD study at two DZL centers - Evaluation of site-specific VOC Source: International Congress 2015 – Exhaled biomarkers in children and adults with airways disease Year: 2015 Presence of volatile organic compounds (VOC) in exhaled breath in patients diagnosed with lung cancer (LC) vs healthy patients. Preliminary data Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Analysis of semi-volatile organic compounds in exhaled breath condensate of patients with obstructive lung diseases Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities Year: 2010 Volatile organic compounds in COPD: Is hexanal an inflammation biomarker? Source: International Congress 2016 – The future of lung function is beginning now Year: 2016 Identification of exhaled volatile organic compounds (VOCs) associated with loss of asthma control Source: International Congress 2016 – Assessing lower airway inflammation with different tools Year: 2016 Concentration profile of persistent organic pollutants (POPs) in blood serum of patients with COPD Source: Annual Congress 2010 - Chemical exposures and respiratory effects Year: 2010 Multiple detectable exhaled volatile organic compounds (vocs) may serve as potential inflammatory biomarkers in COPD Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment Year: 2009 Volatile organic compounds (VOC) in exhaled air sampled through the working channel of a bronchoscope in lung cancer patients Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Exhaled volatile organic compounds as markers for medication use in asthma Source: Eur Respir J, 55 (2) 1900544; 10.1183/13993003.00544-2019 Year: 2020 Breath volatile organic compounds and inflammatory markers in adult asthma patients: negative results from the ALLIANCE cohort Source: Eur Respir J, 57 (2) 2002127; 10.1183/13993003.02127-2020 Year: 2021 Standardization of exhaled volatile organic compounds (VOCs) measurement Source: Annual Congress 2010 - Exhaled biomarkers: smells like disease Year: 2010